Erasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity Signals

  • Erasca Inc ERAS said that due to a lack of clinical activity, it would not continue exploring ERAS-007 combined with palbociclib in patients with RAS-mutated gastrointestinal malignancies or ERAS-007 combined with osimertinib in patients with post-osimertinib EGFR-mutated non-small cell lung cancer.
  • The company will deprioritize certain discovery programs: ERAS-9 (SOS1), ERAS-11 (MYC), and ERAS-2/3 (RAS switch-II groove targeting), but is pursuing other promising research approaches to target RAS mutations beyond G12C. 
  • Erasca also announced preliminary Phase 1b data for ERAS-007 in patients with metastatic BRAF V600E-mutated (BRAFm) colorectal cancer (CRC).
  • 50% (3/6) response rate, including two confirmed partial responses (cPR) and one unconfirmed partial response (uPR), and a 67% (4/6) disease control rate (DCR) was observed at the highest dose of ERAS-007 tested (100 mg BID-QW).
  • Across all dose levels in EC-naïve response evaluable patients, 38% (3/8) response rate, including two cPRs and one uPR, and 63% (5/8) DCR. 
  • ERAS-007 + EC was generally well tolerated, with primarily low-grade treatment-related adverse events (TRAEs) at all combination doses. No Grade 4 or 5 TRAEs were observed.
  • One dose-limiting toxicity was reported for ERAS-007 100 mg BID-QW + EC (Grade 3 macular edema)
  • Price Action: ERAS shares closed at $3.30 on Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!